FELIPE GALVAN: Open Payments
NPI 1841327459 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$6,444 in 297 payments from 24 companies in 2025. Trend: 2023 $4,553 · 2024 $6,142 · 2025 $6,444
Food & beverage: $6,098Education: $346
| Company | Payments | Amount |
|---|---|---|
| UCB, Inc. | 25 | $854 |
| Janssen Biotech, Inc. | 49 | $834 |
| ABBVIE INC. | 42 | $754 |
| Galderma Laboratories, L.P. | 29 | $671 |
| Incyte Corporation | 22 | $465 |
| GENZYME CORPORATION | 16 | $409 |
| Arcutis Biotherapeutics, Inc. | 13 | $302 |
| Ortho Dermatologics, a division of Bausch Health US, LLC | 13 | $274 |
| Janssen Scientific Affairs, LLC | 3 | $245 |
| Amgen Inc. | 13 | $242 |
Products named: TREMFYA, Bimzelx, RINVOQ, NEMLUVIO, DUPIXENT, OPZELURA, OTEZLA, Sotyktu.
Industry payments across TX — which companies pay providers there.
